Total Funding
50
49
Total FundingCorporate Round raised
Growth Score
-8 pts
Heat Score
-12 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
218143
Kringle Pharma is a biopharmaceutical firm that researches and develops drugs to treat intractable diseases.
Kunio Matsumoto: Chief Scientific Officer and Director- Keigo Hanada: Director Pharmaceutical Development Division
About the Company
Kringle Pharma, a biopharmaceutical company, develops pharmaceutical products based on its research on hepatocyte growth factor (HGF) and NK4. Its HGF has the regenerative healing ability in regard to liver cells, as well as various cells and organs, and NK4 is a bi-functional molecule that inhibits the invasion and metastasis of tumor cells as an
HGF antagonist and possesses antiangiogenic activity. The company’s pipeline includes recombinant human HGF for the treatment of acute renal failure, skin ulcers, and CNS diseases, and recombinant human NK4 and NK4 gene drugs for cancer therapy. Kringle Pharma, Inc. was founded in 2001 and is based in Toyonaka, Japan.
